IL293776A - Methods for treating Parkinson's disease - Google Patents

Methods for treating Parkinson's disease

Info

Publication number
IL293776A
IL293776A IL293776A IL29377622A IL293776A IL 293776 A IL293776 A IL 293776A IL 293776 A IL293776 A IL 293776A IL 29377622 A IL29377622 A IL 29377622A IL 293776 A IL293776 A IL 293776A
Authority
IL
Israel
Prior art keywords
gad
aav
nucleic acid
subject
time
Prior art date
Application number
IL293776A
Other languages
English (en)
Hebrew (he)
Original Assignee
Meiragtx Uk Ii Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiragtx Uk Ii Ltd filed Critical Meiragtx Uk Ii Ltd
Publication of IL293776A publication Critical patent/IL293776A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813Exopeptidases (3.4.11. to 3.4.19)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y401/00Carbon-carbon lyases (4.1)
    • C12Y401/01Carboxy-lyases (4.1.1)
    • C12Y401/01015Glutamate decarboxylase (4.1.1.15)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL293776A 2019-12-12 2020-12-14 Methods for treating Parkinson's disease IL293776A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962947418P 2019-12-12 2019-12-12
PCT/US2020/064928 WO2021119615A1 (en) 2019-12-12 2020-12-14 Methods for treating parkinson's disease

Publications (1)

Publication Number Publication Date
IL293776A true IL293776A (en) 2022-08-01

Family

ID=76330812

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293776A IL293776A (en) 2019-12-12 2020-12-14 Methods for treating Parkinson's disease

Country Status (10)

Country Link
US (1) US20230050187A1 (enExample)
EP (1) EP4072568A4 (enExample)
JP (2) JP7758671B2 (enExample)
KR (1) KR20220114028A (enExample)
AU (1) AU2020403266A1 (enExample)
BR (1) BR112022011584A2 (enExample)
CA (1) CA3161322A1 (enExample)
IL (1) IL293776A (enExample)
MX (1) MX2022007193A (enExample)
WO (1) WO2021119615A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2409674C (en) * 2000-05-23 2010-05-11 Neurologix, Inc. Glutamic acid decarboxylase (gad) based delivery systems
US7695959B2 (en) * 2000-05-23 2010-04-13 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
US20030087264A1 (en) * 2001-05-22 2003-05-08 Kaplitt Michael G. Transcriptional regulation of target genes
CA2610164A1 (en) * 2005-05-31 2006-12-07 Neurologix, Inc. Novel glutamic acid decarboxylase (gad) chimera and methods of use
JOP20190269A1 (ar) * 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون

Also Published As

Publication number Publication date
EP4072568A1 (en) 2022-10-19
CA3161322A1 (en) 2021-06-17
AU2020403266A1 (en) 2022-08-04
KR20220114028A (ko) 2022-08-17
BR112022011584A2 (pt) 2022-12-13
JP2025188191A (ja) 2025-12-25
JP2023506007A (ja) 2023-02-14
MX2022007193A (es) 2022-09-19
JP7758671B2 (ja) 2025-10-22
WO2021119615A1 (en) 2021-06-17
EP4072568A4 (en) 2024-02-07
US20230050187A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
US7645446B2 (en) Glutamic acid decarboxylase (GAD) based delivery system
Kohlschütter et al. Current and emerging treatment strategies for neuronal ceroid lipofuscinoses
US7588757B2 (en) Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
Nagahara et al. Potential therapeutic uses of BDNF in neurological and psychiatric disorders
US7955595B2 (en) Glutamic acid decarboxylase (GAD) based delivery system
AU2001268080A1 (en) Glutamic acid decarboxylase (gad) based delivery systems
US9333243B2 (en) Gene delivery vehicles in the treatment of neurodegenerative diseases
US20230050187A1 (en) Methods for Treating Parkinson's Disease
EA051580B1 (ru) Способы лечения болезни паркинсона
CN115135347A (zh) 治疗帕金森病的方法
Elder AADC gene therapy for Parkinson’s disease
WO2026085129A1 (en) High-dose gad gene therapy for treating parkinson's disease
Kells et al. GDNF Gene Therapy for Parkinson’s Disease
US20250360226A1 (en) Oxr1 gene therapy
Simonato et al. Gene Therapy for Neurological Diseases
US20220364118A1 (en) Targeting deltafosb for treatment of dyskinesia
Sahu et al. Gene therapy under clinical trials for neurodegenerative diseases
Bankiewicz et al. GDNF and AADC Gene Therapy for Parkinson’s Disease
JP2025510150A (ja) パーキンソン病の処置のための方法および組成物
TW202608488A (zh) 基因治療
EP4475871A1 (en) Treatment of acquired focal epilepsy
Milkessaa et al. Current Trends in Treatment of Parkinsons Disease using Gene Therapy